The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
Feng Jin
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Michelle Robeson
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Huafeng Zhou
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Grace Hisoire
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Srini Ramanathan
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences